118 related articles for article (PubMed ID: 26762209)
1. FGFR Inhibitor Ameliorates Hypophosphatemia and Impaired Engrailed-1/Wnt Signaling in FGF2 High Molecular Weight Isoform Transgenic Mice.
Du E; Xiao L; Hurley MM
J Cell Biochem; 2016 Sep; 117(9):1991-2000. PubMed ID: 26762209
[TBL] [Abstract][Full Text] [Related]
2. FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.
Du E; Xiao L; Hurley MM
J Cell Physiol; 2017 Mar; 232(3):610-616. PubMed ID: 27306296
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
Xiao L; Du E; Homer-Bouthiette C; Hurley MM
Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of FGFR Signaling Partially Rescues Osteoarthritis in Mice Overexpressing High Molecular Weight FGF2 Isoforms.
Xiao L; Williams D; Hurley MM
Endocrinology; 2020 Jan; 161(1):. PubMed ID: 31901095
[TBL] [Abstract][Full Text] [Related]
5. FGF23 Regulates Wnt/β-Catenin Signaling-Mediated Osteoarthritis in Mice Overexpressing High-Molecular-Weight FGF2.
Meo Burt P; Xiao L; Hurley MM
Endocrinology; 2018 Jun; 159(6):2386-2396. PubMed ID: 29718273
[TBL] [Abstract][Full Text] [Related]
6. FGF23 Neutralizing Antibody Partially Improves Bone Mineralization Defect of HMWFGF2 Isoforms in Transgenic Female Mice.
Xiao L; Homer-Bouthiette C; Hurley MM
J Bone Miner Res; 2018 Jul; 33(7):1347-1361. PubMed ID: 29502359
[TBL] [Abstract][Full Text] [Related]
7. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.
Xiao L; Naganawa T; Lorenzo J; Carpenter TO; Coffin JD; Hurley MM
J Biol Chem; 2010 Jan; 285(4):2834-46. PubMed ID: 19933269
[TBL] [Abstract][Full Text] [Related]
8. FGF receptor inhibitor BGJ398 partially rescues osteoarthritis-like phenotype in older high molecular weight FGF2 transgenic mice via multiple mechanisms.
Hurley MM; Coffin JD; Doetschman T; Valera C; Clarke K; Xiao L
Sci Rep; 2022 Sep; 12(1):15968. PubMed ID: 36153352
[TBL] [Abstract][Full Text] [Related]
9. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro.
Xiao L; Esliger A; Hurley MM
J Bone Miner Res; 2013 Jan; 28(1):35-45. PubMed ID: 22836867
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
[TBL] [Abstract][Full Text] [Related]
11. FGF2 High Molecular Weight Isoforms Contribute to Osteoarthropathy in Male Mice.
Meo Burt P; Xiao L; Dealy C; Fisher MC; Hurley MM
Endocrinology; 2016 Dec; 157(12):4602-4614. PubMed ID: 27732085
[TBL] [Abstract][Full Text] [Related]
12. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
13. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
[TBL] [Abstract][Full Text] [Related]
14. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
Farrow EG; Summers LJ; Schiavi SC; McCormick JA; Ellison DH; White KE
J Endocrinol; 2010 Oct; 207(1):67-75. PubMed ID: 20675303
[TBL] [Abstract][Full Text] [Related]
15. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast Growth Factor 2 High Molecular Weight Isoforms in Dentoalveolar Mineralization.
Millington G; Joseph J; Xiao L; Vijaykumar A; Mina M; Hurley MM
Calcif Tissue Int; 2022 Jan; 110(1):93-103. PubMed ID: 34245331
[TBL] [Abstract][Full Text] [Related]
17. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.
Suvannasankha A; Tompkins DR; Edwards DF; Petyaykina KV; Crean CD; Fournier PG; Parker JM; Sandusky GE; Ichikawa S; Imel EA; Chirgwin JM
Oncotarget; 2015 Aug; 6(23):19647-60. PubMed ID: 25944690
[TBL] [Abstract][Full Text] [Related]
18. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule.
Portale AA; Zhang MY; David V; Martin A; Jiao Y; Gu W; Perwad F
PLoS One; 2015; 10(11):e0142924. PubMed ID: 26588476
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor-2 stimulates proliferation of human adipose-derived stem cells via Src activation.
Ma Y; Kakudo N; Morimoto N; Lai F; Taketani S; Kusumoto K
Stem Cell Res Ther; 2019 Nov; 10(1):350. PubMed ID: 31775870
[TBL] [Abstract][Full Text] [Related]
20. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.
Goetz R; Nakada Y; Hu MC; Kurosu H; Wang L; Nakatani T; Shi M; Eliseenkova AV; Razzaque MS; Moe OW; Kuro-o M; Mohammadi M
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):407-12. PubMed ID: 19966287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
